Axsome Therapeutics Supports Migraine Awareness
Analysis based on 6 articles · First reported Jun 01, 2026 · Last updated Jun 01, 2026
This event is expected to have a slightly positive impact on the market sentiment for Axsome Therapeutics as it demonstrates corporate social responsibility and raises awareness for a condition it treats. Increased public awareness of migraine could also indirectly benefit the broader pharmaceutical and healthcare industries focused on CNS disorders.
Axsome Therapeutics is supporting Migraine and Headache Awareness Month in June 2026 through various educational initiatives. The company is partnering with The Headache Alliance and the Alliance for Headache Disorders Advocacy to highlight the impact of migraine. Key activities include supporting the first annual 'Headache in the City' educational campaign on June 15 in United States — New York City, and lighting Axsome Therapeutics' headquarters, United States — One World Trade Center, in purple on June 4 for migraine awareness. Axsome Therapeutics is also sharing resources from organizations like the American Migraine Foundation, Association of Migraine Disorders, Coalition for Headache and Migraine Patients, and National Headache Foundation to help patients find doctors, understand migraines, access financial assistance, and learn about treatments.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard